General Psychiatry
General Psychiatry RSS Feed RSS

Adderall and Death: It’s Team FDA versus Team Canada!

April 1, 2005
Daniel Carlat, MD
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
On February 9, 2005, Health Canada (HC) announced that it was suspending sales of Adderall XR in Canada because of concerns that it might lead to sudden death and stroke. The FDA, however, has begged to differ.
Read More

Lawrence H. Diller, MD, on The Use of Stimulants in ADHD

April 1, 2005
Lawrence H. Diller, MD
Lawrence H. Diller, MDLawrence H. Diller, MD Assistant Clinical Professor, UCSF School of Medicine Author, Running on Ritalin and Should I Medicate My Child? Dr. Diller has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.


Dr. Diller, you’re a rare bird in the ADHD world in that you are skeptical of our reliance on stimulants for treating this condition, and yet you have an unusually good grasp and appreciation of how and when to use them. What is your background?
Read More

The Dark Side of Stimulants

April 1, 2005
Daniel Carlat, MD
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Amphetamine was first synthesized in Germany in 1887. It became popular as a recreational drug in the US in the 1930s. While cocaine was declared illegal in 1914, amphetamines were widely available, and were often used by college students and truck drivers.
Read More

How to Sniff Out Bias in CME Programs

March 1, 2005
Daniel Carlat, MD
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
So, you want to be a bias-buster? Gird yourself, because it’s not an easy task. In order to establish the presence of commercial bias, you have to demonstrate two things: first, that the activity is funded by industry; and second, that the content of the program is unreasonably slanted toward the sponsor’s product.
Read More

Journal Articles as Marketing: Tricks of The Trade

March 1, 2005
Daniel Carlat, MD
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
It probably comes as little surprise to most readers that manufacturer-sponsored research is more likely to yield an outcome favorable to the sponsored product than similar non-sponsored research. What may be surprising is that there is actually a good-sized body of published research (non-sponsored, of course!) on this very topic.
Read More

Jerome P. Kassirer, M.D., on Conflict of Interest in Medicine

March 1, 2005
Jerome P. Kassirer, M.D.
Jerome P. Kassirer, M.D.Jerome P. Kassirer, M.D.

Distinguished Professor, Tufts University School of Medicine Editor-in-Chief Emeritus, New England Journal of Medicine. Author, On The Take: How Medicine’s Complicity with Big Business Can Endanger Your Health (Oxford University Press, 200
Dr. Kassirer has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity. 

Dr. Kassirer, thanks for agreeing to share some of your thoughts with our readers. I have to say that your book, On The Take, was one of the most powerful books I’ve read. I want to thank you for writing it!
Read More

CME Bias: ACCME to the Rescue!

March 1, 2005
Daniel Carlat, MD
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
There is trouble for the pharmaceutical industry in CME City. The ACCME (Accreditation Council for Continuing Medical Education), which sets national standards for accredited CME activities, has tightened up its requirements for commercial support, which is giving drug companies, private medical education firms, and assorted hired guns a collective case of indigestion.
Read More

Anecdote from the Field: I Was a Middle-Aged Drug Whore!

March 1, 2005
Daniel Carlat, MD
Daniel J. Carlat, M.D., is the editor-in-chief of The Carlat Report.
Many readers have wondered why I decided to publish The Carlat Report. Well, back in the day, I was a member of the speaker’s bureau of four pharmaceutical companies. I would typically travel to the offices of primary care physicians nearby and talk up the sponsor’s drug.
Read More

The FDA and Big Pharma: A Turning Point

March 1, 2005
Daniel Carlat, MD
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
1992 was a very big year in the history of the relationship between the FDA and the pharmaceutical industry. That year, Congress passed the Prescription Drug User Fee Act (PDUFA), allowing the FDA to charge pharmaceutical companies hundreds of thousands of dollars per drug for the drug approval process.
Read More
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
Featured Video
Featured Podcast
Recommended

About

Shop Online

Newsletters

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2024 Carlat Publishing, LLC and Affiliates, All Rights Reserved.